1. Home
  2. miRNA
  3. hsa-miR-23a-3p miREIA

hsa-miR-23a-3p miREIA

Regulatery Status: RUO
Type: miREIA – miRNA enzyme immunoassay
Species: Human
Catalog No Size
Product Catalog No: RDM0009H Pack Size: 96 wells (1 kit)

Pack Size:
Pack Size:
Pack Size:
Pack Size:

Category:
Techical Sheet / Info

Type

miREIA – miRNA enzyme immunoassay

Applications

Whole blood

Sample Requirements

10 µl/well

Storage/Expiration

Store the complete kit at 2 – 8 °C. Under these conditions, all components are stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

12.5 – 0.39 amol/μl

Limit of Detection

0.13 amol/μl

Intra-assay (Within-Run)

n = 8,
CV = 5.1%

Inter-assay (Run-to-Run)

n = 5,
CV = 6.3%

Spiking Recovery

96.1%

Dilutation Linearity

98.5%

Order Enquiry

    Order Enquiry Form

    References
    1. Chhabra, Ravindresh, Richa Dubey, and Neeru Saini. “Cooperative and individualistic functions of the microRNAs in the miR-23a~ 27a~ 24-2 cluster and its implication in human diseases.” Molecular cancer 9.1 (2010): 232.
    2. Mi, Shuangli, et al. “MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia.” Proceedings of the National Academy of Sciences104.50 (2007): 19971-19976.
    3. Li, Xiaoni, et al. “c-MYC-regulated miR-23a/24-2/27a cluster promotes mammary carcinoma cell invasion and hepatic metastasis by targeting Sprouty2.” Journal of Biological Chemistry 288.25 (2013): 18121-18133.
    4. Ma, Gang, et al. “Upregulation of microRNA-23a/b promotes tumor progression and confers poor prognosis in patients with gastric cancer.” International journal of clinical and experimental pathology 7.12 (2014): 8833.
    5. Tian, K., R. Di, and L. Wang. “MicroRNA-23a enhances migration and invasion through PTEN in osteosarcoma.” Cancer gene therapy 22.7 (2015): 351-359.
    6. Chen, Ping, et al. “MiR-23a modulates X-linked inhibitor of apoptosis-mediated autophagy in human luminal breast cancer cell lines.” Oncotarget 8.46 (2017): 80709.
    7. Yu, Zhi-wei, et al. “MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines.” Oral oncology 46.4 (2010): 317-322.
    8. Jin, Ai-Hong, and Zhao-Lian Wei. “Molecular mechanism of increased sensitivity of cisplatin to ovarian cancer by inhibition of microRNA-23a expression.” International journal of clinical and experimental medicine 8.8 (2015): 13329.
    9. Feldman, Andre, et al. “Analysis of Circulating miR‐1, miR‐23a, and miR‐26a in Atrial Fibrillation Patients Undergoing Coronary Bypass Artery Grafting Surgery.” Annals of human genetics 81.3 (2017): 99-105.
    10. Xiong, Weixi, et al. “Circulatory microRNA 23a and microRNA 23b and polycystic ovary syndrome (PCOS): the effects of body mass index and sex hormones in an Eastern Han Chinese population.” Journal of ovarian research 10.1 (2017): 10.
    11. Nie, Mao, et al. “Noncoding RNAs, emerging regulators of skeletal muscle development and diseases.” BioMed research international 2015 (2015).
    12. Wang, Fei, et al. “Serum miRNAs miR-23a, 206, and 499 as Potential Biomarkers for Skeletal Muscle Atrophy.” BioMed Research International 2017 (2017).
    Documents
    Enquiry